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existing hypertension, diabetes, and a slightly elevated overall
severity of illness when clopidogrel was first prescribed.
To adjust for these differences, a subset of members was con-
structed within each group who all had diagnoses of ischemic heart
disease, congestive heart failure, hypertension, hyperlipidemia, and
diabetes before the start of clopidogrel therapy. Table 1 shows that
differences in acute MI rates between the control and high PPI groups
remained significant (p  0.05) when these comorbidity differences
were adjusted out of the analysis. Relative risk for acute MI in the high
PPI exposure group was 337% greater than in the control group.
Although claims-based analyses are limited and cannot control
for variables such as years of risk factor presence, weight gain,
smoking history, and family history of coronary heart disease, we
feel that evidence is pointing toward a potentially significant
interaction between PPIs and clopidogrel that may decrease the
ability of clopidogrel to prevent acute MI events.
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Reply
We thank Dr. Pezalla and colleagues for their interest in our article
(1). We are highly interested in the strong link reported between
proton pump inhibitor (PPI) use and clinical coronary artery
adverse events in patients under clopidogrel therapy, according to
their medical and pharmacy databases.
Our study showed that omeprazole significantly decreased the
clopidogrel inhibitory effect on platelet P2Y12 as assessed by the
vasodilator-stimulated phosphoprotein (VASP) phosphorylation
test. This study has opened the way to a clinical validation of this
concept. A first step was reached by a report from another French
team showing a sensitivity of 100% of the VASP test in predicting
major adverse cardiac events (MACE) (2). Moreover, Bonello
et al. (3) showed that adjusting the clopidogrel loading dose
according to the VASP index, before PCI, in daily clinical practice
improved the clinical outcome after coronary stenting.
Data reported in the letter by Dr. Pezalla and colleagues tend to
confirm that adding PPI to an antiplatelet therapy with clopidogrel
increases MACE.
A strong link seems to exist between clopidogrel–PPI interac-
tion, VASP index, and clinical outcomes. However, some ques-
tions remain. Are all PPIs equal? When co-prescription of clopi-
dogrel and PPI is mandatory, what is the best attitude? A VASP test
may be performed and clopidogrel dose may be adjusted to obtain a
VASP index higher than 50% (4–6). According to Bonello et al. (3),
an additional bolus dose of clopidogrel may decrease clinical events,
but how long should high doses be maintained?
Additional randomized trials with clinical end points must be
performed. Nevertheless, biological data from our randomized
double-blind trial, confirmed by clinical results of registries such as the
one reported in the letter by Dr. Pezalla and colleagues, should lead us
to avoid systematic addition of PPI when clopidogrel is prescribed.
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Comparison of 1-Year Acute Myocardial Event Rates inRisk-Adjusted Members Receiving Clopidogrel Wi h andWithout Concomitant PPI Use
Table 1
Comparison of 1-Year Acute Myocardial Event Rates in
Risk-Adjusted Members Receiving Clopidogrel With and
Without Concomitant PPI Use
Control
(Clopidogrel,
No PPI)
Low PPI
Exposure
High PPI
Exposure
Members with all
identified risk
factors, n
384 90 536
Age (yrs) 58.24 4.68 58.32 5.79 57.12 5.80
Male gender, n (%) 257 (66.92) 58 (64.4) 365 (68.09)
Members with MI
events, n
10 9 61
Members with MI
events, %
2.60 10.00 11.38
95% confidence
interval
1.01–4.19 3.81–16.19 8.69–14.07
MI  myocardial infarction; PPI  proton pump inhibitor.
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